Home Tags Clinical trials

Tag: clinical trials

In the War Against Brain Cancer, Accelerated Clinical Trials Are a...

More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain and Ted Kennedy – is...

Pivotal Trial of Enfortumab Vedotin Shows Positive Topline Results in Locally...

The first cohort of patients in a pivotal phase II single-arm clinical trial, known as EV-201, shows positive topline results. EV-201 is an ongoing...

Study looks at Efficacy and Metabolism of Azonafide-based ADCs in Microgravity

A new study is investigating the efficacy and metabolism of azonafide-based antibody-drug conjugates (ADCs) in microgravity. The investigators seeks to activate immunogenic cell death...

European Commission Approves Label Variation for Brentuximab Vedotin

The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include data on the...

Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...

Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...

SGN-CD19A Shows Encouraging Antitumor Activity in Recurrent Non-Hodgkin Lymphoma and...

Results from two ongoing phase I clinical trials evaluating SGN-CD19A (Seattle Genetics), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies,...

Sneaking Medicines Across the Blood-Brain Barrier

Research published in the November 2014 edition of The FASEB Journal, published by the Federation of the American Societies for Experimental Biology, suggests that a very small single domain antibody called FC5 has proven able to cross the blood-brain barrier (BBB). This opens the door to new treatments for a multitude of brain diseases.
Chronic Lymphocytic Leukemia

Novel IgM-derived Antibody-drug Conjugate Targets Fcμ-receptor in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia or CLL, one of the most common forms of leukemia in Europe and North America, is a disorder of morphologically mature...

FEATURED RESOURCES